Insulin like growth factors axis and growth disorders

Indian Journal of Pediatrics

Volumn 73, Issue 1, 2006, Pages 67-71

  Anurag, Bajpai ^a   Menon, P S N ^b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b Armed Forces Hospital Kuwait   (Kuwait)

Author keywords

Growth disorders; Insulin like growth factor binding proteins (IGFBP); Insulin like growth factors (IGF)

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; SOMATOMEDIN;

ALZHEIMER DISEASE; BRAIN HYPOXIA; BRAIN ISCHEMIA; BRAIN PSEUDOTUMOR; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; ENDOCRINE SYSTEM; GROWTH DISORDER; GROWTH HORMONE DEFICIENCY; GROWTH REGULATION; HORMONE ACTION; HORMONE RESISTANCE; HUMAN; HYPOGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIPOHYPERTROPHY; PROVOCATION TEST; PSORIASIS; BODY HEIGHT; CHILD; CHILD DEVELOPMENT; HYPOTHALAMUS HYPOPHYSIS SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

BODY HEIGHT; CHILD; CHILD DEVELOPMENT; GROWTH DISORDERS; GROWTH HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; SOMATOMEDINS;

EID: 33745957599     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02758264     Document Type: Conference Paper

References (27)

1. Rosenfield GR, Cohen P. Disorders of growth hormone/insulin like growth factor and action. In Sperling MA, ed. Pediatric Endocrinology. 2nd edn. Philadelphia; WB Saunders, 2002; 211-288.
2. Le Roith D, Bondy C, Yakar S et al . The somatomedin hypothesis: 2001. Endocr Rev 2001; 22: 53-74.
3. Salmon WD, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med 1957; 49: 825-836.
4. Zapf J, Rinderknecht E, Humbel RE et al. Nonsuppressible insulin-like activity (NSILA) from human serum: recent accomplishments and their physiologic implications. Metabolism 1978; 27: 1803-1828.
5. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 25: 2769-2776.
6. Monzavi R, Cohen P. IGFs and IGFBPs: role in health and disease. Best Pract Res Clin Endocrinol Metab 2002; 16: 433-447.
7. Sizonenko PC, Clayton PE, Cohen P et al. Diagnosis and management of growth hormone deficiency in childhood and adolescence. Part 1: diagnosis of growth hormone deficiency. Growth Horm IGF Res 2001; 11: 137-165.
8. Wetterau LA, Moore MG, Lee KW et al. Novel aspects of the insulin-like growth factor binding proteins. Mol Genet Metab 1999; 68: 161-181.
9. Lupu F, Terwilliger JD, Lee K et al. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001; 229: 141-162.
10. Woods KA, Camacho-Hubner C, Barter D et al. Insulin-like growth factor I gene deletion causing intrauterine growth retardation and severe short stature. Acta Paediatr Suppl 1997; 423: 39-45.
11. Rosenfeld RG, Wilson DM, Lee PD, et al. Insulin-like growth factors I and II in evaluation of growth retardation. J Pediatr 1986; 109: 428-433.
12. Blum WF, Ranke MB. Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders. Horm Res 1990; 33 Supp l 4: 31-37.
13. Blum WF, Cotterill AM, Postel-Vinay MC et al . Improvement of diagnostic criteria in growth hormone insensitivity syndrome: solutions and pitfalls. Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes. Acta Paediatr Suppl 1994; 399: 117-124.
14. Lee KW, Cohen P. Individualized growth hormone therapy in children: advances beyond weight-based dosing. J Pediatr Endocrinol Metab 2003; 16 Suppl 3: 625-630.
15. Park P, Cohen P. The role of insulin-like growth factor I monitoring in growth hormone-treated children. Horm Res 2004; 62 Suppl 1: 59-65.
16. Shim M, Cohen P. IGFs and human cancer: implications regarding the risk of growth hormone therapy. Horm Res 1999; 51 Suppl 3: 42-51.
17. Laron Z, Klinger B, Erster B et al. Effect of acute administration of insulin-like growth factor I in patients with Laron-type dwarfism. Lancet 1988; 19: 1170-1172.
18. Guevara-Aguirre J, Rosenbloom AL, Vasconez O et al . Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab 1997; 82: 629-633.
19. Azcona C, Preece MA, Rose SJ et al . Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype. Clin Endocrinol (Oxf) 1999; 51: 787-792.
20. Backeljauw PF, Underwood LE; GHIS Collaborative Group. Growth hormone insensitivity syndrome. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 2001; 86: 1504-1510.
21. Ranke MB, Savage MO, Chatelain PG et al . Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 1999; 51: 128-134.
22. Shaw NJ, Fraser NC, Rose S et al . Bone density and body composition in children with growth hormone insensitivity syndrome receiving recombinant IGF-I. Clin Endocrinol (Oxf) 2003; 59: 487-491.
23. Underwood LE, Backeljauw P, Duncan V, GHIS Collaborative Group. Effects of insulin-like growth factor I treatment on statural growth, body composition and phenotype of children with growth hormone insensitivity syndrome. Acta Paediatr Suppl 1999; 88 : 182-184.
24. Brain CE, Hubbard M, Preece MA et al . Metabolic status of children with growth hormone insensitivity syndrome and responses to treatment with IGF-I. Horm Res 1998; 50: 61-70.
25. Guan J, Waldvogel HJ, Faull RL et al. The effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate in different regions following hypoxic-ischemic brain injury in adult rats. Neuroscience 1999; 89: 649-659.
26. Wraight CJ, White PJ, McKean SC et al. Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides. Nat Biotechnol 2000; 18: 521-526.
27. Carro E, Trejo JL, Gomez-Isla T et al. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 2002; 8: 1390-1397.